PRR Project
Assistant researcher
Project sheet
Name
Assistant researcherTotal project amount
246,79 thousand €Amount paid
0 €Non-refundable funding
246,79 thousand €Loan funding
0 €Start date
01.02.2025Expected end date
31.03.2026Dimension
ResilienceComponent
Qualifications and SkillsInvestment
Science Plus TrainingOperation code
02/C06-i06/2024.P2023.13694.TENURE.010Summary
RISE (Rede de Investigação em Saúde) aims to hire a highly motivated and accomplished Assistant Researcher in Nucleic Acid-based Therapies to join its research team. The successful candidate will support and expand a research program focused on developing novel nucleic acid-based therapies targeting various human diseases. Rationale :Early medicines were based on small molecule compounds derived from nature, but many demonstrated a lack of specificity and unwanted side effects. With the advent of molecular medicine, clinicians aimed to target and modulate specific proteins associated with one or more diseases. Amino acid-based therapeutics (e.g., recombinant insulin and antibodies) have gradually dominated the clinical space for decades due to their higher specificity and reduced side effects. Nucleic acid-based therapeutics have only recently come into the spotlight with the regulatory approval of small interfering RNAs (siRNAs) and the major success of mRNA-based vaccines against COVID-19. Additionally, the pharmaceutical industry is investing heavily in emerging CRISPR-inspired technologies, such as base/prime editors, as well as other RNA-based platforms. Importantly, these therapies can be easily modified to accommodate potential polymorphisms in the individual patient’s genome; thus, leading to the era of truly personalized medicine.RISE is committed to advancing health research in Portugal/Europe and promoting translational research that bridges the gap between basic science and clinical applications. The hiring of an Assistant Researcher in Nucleic Acid-based Therapies aligns with RISE´s mission to strengthen the development of novel therapies targeting diseases in which fellow RISE researchers of basic/clinical science have expertise, including glaucoma, neuroinflammation, and beyond.The Assistant Researcher in Nucleic Acid-based Therapies will play a key role in all aspects of the relevant research projects, including 1) experimental design and execution, 2) keeping up-to-date with the current science and technologies, 3) publication and communication of results, 4) protection of intellectual property, 5) mentoring junior researchers and 6) collaborating with other research groups within RISE and external partners. The academic and industrial expertise of the Assistant Researcher will be leveraged to help identify and characterize novel nucleic acid-based therapies against current and future targets relevant to RISE researchers.This position will allow RISE to further translate the work of its researchers and clinicians into actionable therapies. Importantly, these novel therapeutics may result in intellectual property; thus, providing additional capital to RISE that can then feed back into continued research for all. Scientific Profile ???????:The ideal candidate will have:1) A PhD or equivalent degree in Biotechnology in Human Health or related field.2) A proven track record of peer-reviewed international publications and congress communications, including as primary author, in the fields of nucleic-acid therapy, biotechnology, drug delivery, and basic cellular biology.3) Expertise in developing the technical knowledge and assays needed to identify, and elucidate the functional efficacy of, novel medicines, including quantitative PCR, Western Blotting, ELISA, SELEX, bioinformatics, and flow cytometry (FACS).4) Demonstrated the ability to manage projects from their conception to resolution which includes executing the daily activities and adapting the line of research as the data and science necessitates.5) Strong communication and collaboration skills, with the ability to work effectively within a multidisciplinary and multicultural research environment.6) Experience in managing a laboratory and junior researchers.7) Expertise in drug discovery in both academia and industry.8) Established a network of expert researchers with varied skills and resources in academia and industry.
Beneficiaries
The two types are::
- Direct Beneficiaries are those whose funding and projects to implement are part of the Recovery and Resilience Plan that has been negotiated and approved by the European Union;
- Final Beneficiaries are those whose funding and projects to implement are approved following a selection process through Calls for Applications.
Call for applications
As part of the Call for Applications, submissions are requested to select the projects and final beneficiaries to whom funding will be awarded. Specific selection criteria are defined for each call, which must be reflected in the applications submitted and assessed.
The project is appraised on the basis of its compliance with the selection criteria laid down in the calls for applications, and a final score may be awarded, where applicable.
Final evaluation score
The components for calculating the assessment score can be found in the selection criteria document mentioned below.
Selection criteria
Beneficiaries
Intermediate beneficiaries
Procurement
Beneficiaries representing public entities implement their project by signing one or more contracts with suppliers for goods or services through public procurement procedures.
To ensure and provide the utmost transparency in all these contracts, a list of the contracts that were signed under this project is available here, along with the information available on the Base.Gov platform. Please note that, according to the legislation in force at the time the contract was signed, some exceptions do not require the publication of the contracts signed on this platform, and, therefore, no information is available in such cases.
Geographic distribution
246,79 thousand €
Total amount of the project
Where was the money spent
By county
1 county financed .
-
Porto 246,79 thousand € ,